Omeros’ (OMER) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Omeros (NASDAQ:OMER) in a research report released on Friday morning,Benzinga reports. D. Boral Capital currently has a $36.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Tuesday, April 1st. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Performance

NASDAQ OMER opened at $6.73 on Friday. Omeros has a twelve month low of $2.97 and a twelve month high of $13.60. The stock has a market cap of $390.77 million, a price-to-earnings ratio of -2.91 and a beta of 2.35. The firm’s 50 day moving average price is $8.21 and its two-hundred day moving average price is $7.77.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.08. During the same quarter last year, the business posted ($0.15) earnings per share. On average, research analysts forecast that Omeros will post -3.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Omeros

Several institutional investors have recently added to or reduced their stakes in OMER. Nomura Holdings Inc. lifted its position in Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after buying an additional 430,932 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Omeros in the 4th quarter valued at $1,488,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Omeros in the fourth quarter valued at about $1,120,000. Jacobs Levy Equity Management Inc. bought a new stake in Omeros in the fourth quarter valued at approximately $1,033,000. Finally, Ancora Advisors LLC raised its stake in Omeros by 1,036.4% during the 4th quarter. Ancora Advisors LLC now owns 85,800 shares of the biopharmaceutical company’s stock worth $848,000 after buying an additional 78,250 shares during the period. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.